ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Long Term Longitudinal TTV Measurements in Lung Transplant Recipients

E. Gore1, C. Rondaan1, E. A. Verschuuren2, L. Gard1, H. G. Niesters1, C. van Leer-Buter1

1Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 2Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

Meeting: 2022 American Transplant Congress

Abstract number: 1560

Keywords: Immunosuppression, Lung transplantation, Mortality, N/A

Topic: Basic Science » Basic Clinical Science » 17 - Biomarkers: Clinical Outcomes

Session Information

Session Name: Biomarkers: Clinical Outcomes

Session Type: Poster Abstract

Date: Tuesday, June 7, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: To investigate how levels of Torque Teno Virus (TTV), a virus which has been proposed as a marker for immunosuppression change over a period of time following lung transplantation (LTx).

*Methods: 39 LTx patients transplanted between August 2014 and April 2016 were enrolled. All patients received induction therapy with basiliximab and initial maintenance therapy with tacrolimus (targeted trough levels of between 7 and 10 ug/l from month four), prednisolone and mycophenolate mofetil. TTV loads were measured every 4-6 weeks in the first year after transplantation, every 12-16 weeks in the second year and every 6-12 months thereafter using the Biomerieux R-gene TTV detection kit. Patient data was recorded, including reasons for transplantation, rejections episodes, infections, drug level adjustments, development of lung function and outcome after 5 years.

*Results: At month one TTV was Log 5.49 [IQR 4.17 – 6.05], at month six log 6.90 [IQR 5.74 – 7.88]. Peak TTV occurred a median 160 [IQR 99 – 231] days post-transplantation and ranged between log 7.46 and log 8.27. Patient demographics is included in Table 1. Eight patients died during follow-up of these 37% died due to an infectious cause.

Table 1. Patient demographics
Female gender, n (%) 23 (59)
Median Age 54
Reason for transplant, n (%)
Emphysema 16 (41)
Cystic Fibrosis 4 (10)
Fibrotic disease 4 (10)
Retransplant 5 (13)
Other 2 (5)
Mortality, n (%) 8 (20)
Median survival, years (IQR) 6.3 (5.9 – 6.7)

*Conclusions: TTV has been investigated as a marker for immunosuppression following solid organ transplantation. This study is the first to investigate the TTV loads over a prolonged period of time (up to 5 years). Our data shows that lung transplant recipients have a wide range of TTV loads. In spite of all receiving similar immunosuppression, peak TTV levels range from undetectable values to log 8.91. This potentially indicates a significant discrepancy between the pharmacological and the biological effects of antirejection treatment.

The highest TTV loads were measured between three and eight months after transplantation, potentially indicating a reduced level of immunocompetence. This is of importance when considering when to stop prophylaxis, e.g for CMV. Additionally clinicians should be aware that their patients may be at a higher risk of post-transplant infection during this time frame.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Gore E, Rondaan C, Verschuuren EA, Gard L, Niesters HG, Leer-Buter Cvan. Long Term Longitudinal TTV Measurements in Lung Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-longitudinal-ttv-measurements-in-lung-transplant-recipients/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences